Lymph node mapping using indocyanine green (ICG) in cervical carcinoma

Lymph node mapping using indocyanine green (ICG) in cervical carcinoma - LIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00014692

Enrollment

Registered

2018-05-28

Start date

2018-04-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C53

Interventions

Group 1: Evaluation of the medical records of the patients included in the study. The frequency of successful unilateral and bilateral ICG mapping is to be tested and also whether all affected lymph n

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cervical cancer who underwent lymph node mapping using indocyanine green (ICG) at the St. Marien Amberg Clinic between August 2015 and May 2018; patients consent

Exclusion criteria

Exclusion criteria: No consent

Design outcomes

Primary

Measure	Time frame
Aim of this study is to evaluate the frequency of successful unilateral and bilateral ICG mapping and also whether all affected lymph nodes could be identified by ICG.	—

Countries

Germany

Contacts

Public ContactAnton Scharl

Klinik für Frauenheilkunde und Geburtshilfe

scharl.anton@klinikum-amberg.de09621/38-1371

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 28, 2026